Charles River Labs Reports $144M Net Loss Driven by $376M Impairments, But Clears NHP Investigations & Authorizes $1B Buyback

summarizeSummary

Charles River Laboratories reported a net loss of $144.3 million for fiscal year 2025, primarily due to $376.0 million in non-cash impairment charges, but also announced the closure of NHP supply chain investigations and a new $1.0 billion share repurchase program.

check_boxKey Events

• Reports Significant Net Loss and Impairments

  The company reported a net loss of $144.3 million for fiscal year 2025, a substantial decline from a net income of $10.3 million in 2024. This was primarily driven by $376.0 million in non-cash impairment charges, including $211.0 million for intangible assets and $165.0 million for goodwill.

• DOJ and SEC NHP Investigations Concluded

  The U.S. Department of Justice (DOJ) and U.S. Fish and Wildlife Service (USFWS) closed their investigations into the company's non-human primate (NHP) supply chain in August 2025. Additionally, the SEC concluded its inquiry in November 2025, stating it does not intend to recommend an enforcement action.

• Authorizes New $1.0 Billion Share Repurchase Program

  The Board of Directors approved a new $1.0 billion stock repurchase authorization in October 2025, replacing the prior program. This indicates a strong commitment to returning capital to shareholders.

• Strategic Acquisitions Completed Post-Fiscal Year

  Subsequent to fiscal year-end, the company completed the $510.0 million acquisition of K.F. (Cambodia) Ltd., an NHP supplier, and exercised an option to acquire PathoQuest SAS for approximately $60.0 million, expanding its manufacturing quality-control testing solutions.

auto_awesomeAnalysis

This annual report reveals a challenging fiscal year 2025 for Charles River Laboratories, marked by a significant net loss and substantial non-cash impairment charges. However, the filing also brings crucial positive developments, including the closure of major government investigations into its non-human primate (NHP) supply chain and a new, large share repurchase authorization. Investors will need to weigh the poor financial performance against the removal of significant regulatory and legal overhangs, and the company's commitment to shareholder returns and strategic growth through acquisitions and cost-saving initiatives.